Project Grant R21NS146830
- Federal Grant Award Summary Yale University received a $583,646 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded March 20, 2026, with completion scheduled for November 30, 2030. The grant funds research investigating cilia disassembly and dysfunction as a shared pathogenic mechanism across multiple malformations of cortical development...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $236,250 to the University of California, Los Angeles (UCLA) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) on May 15, 2026, with completion targeted for April 30, 2028. This R21 Project Grant supports research investigating the relationship between T cell senescence and chronic inflammatory demyelinating polyneuropathy...
- Federal Grant Award Summary This $230,925 Project Grant, awarded August 1, 2025, by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), supports a five-year research initiative at Yale University examining central nervous system inflammation in aneurysmal subarachnoid hemorrhage (ASAH) patients. The project investigates whether the duration of the pro-inflammatory phase...
- Federal Grant Award Summary Yale University received a $446,670 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 6, 2026, with a completion date of June 30, 2028. The research project centers on the development and validation of bi-functional helical peptides designed to inhibit transactive response DNA binding protein 43 (TDP-43)...
- Federal Grant Award Summary Yale University received a $251,375 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 2, 2025, with a completion date of August 31, 2027. The grant supports research to identify new antigens in seronegative myasthenia gravis (SNMG), an autoimmune neuromuscular disorder characterized by the absence of detectable autoantibodies to known...
- Federal Grant Award Summary Yale University received a $471,402 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective July 1, 2025, through June 30, 2030. The award supports fundamental neuroscience research investigating the role of potassium channels in neuronal development and brain organization. Specifically, the research examines how the...
- Summary of Federal Project Grant Award Yale University received a $461,197 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded on March 17, 2026, with a completion date of February 29, 2028. The primary deliverable is the development of plasma-based biomarkers for stratifying amyotrophic lateral sclerosis (ALS) patients into distinct molecular...
- Federal Grant Award Summary Yale University received a $1.26M Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) on May 9, 2025, with completion targeted for April 30, 2030. This research initiative examines anticoagulation therapy outcomes in intracerebral hemorrhage (ICH) survivors with atrial fibrillation (AF), with particular focus on how cerebral...
- Federal Grant Award Summary Yale University received a $1,270,816 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective May 9, 2025 through April 30, 2030. The grant supports research to decipher the gene regulatory networks (GRNs) that control the establishment, expansion, and maintenance of radial glia—the stem cells of the human...
- Federal Grant Award Summary Yale University received a $251,313 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded August 1, 2025, with completion targeted for July 31, 2027. The project aims to prospectively identify hypoxic-ischemic brain injury (HIBI) in cardiac arrest patients using portable low-field magnetic resonance imaging (MRI),...
Yale University received a $246,347 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective March 20, 2026, through February 29, 2028. The award funds research investigating skin biopsy as a potential biomarker for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare autoimmune disorder affecting the peripheral nervous system. The project addresses a significant clinical need by developing a minimally invasive diagnostic and treatment response assessment tool, as current electrodiagnostic methods lack sensitivity and established blood biomarkers for CIDP remain unavailable. The research deliverables include development and validation of skin punch biopsy methodology to identify inflammation and demyelination in CIDP patients, with the goal of improving diagnostic accuracy and treatment response monitoring in clinical settings. This work aims to overcome current limitations in CIDP diagnosis and management by establishing a practical, validated biomarker that can be routinely applied in outpatient clinical practice, thereby advancing clinical care for this heterogeneous patient population with variable treatment responses.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $246.3k | 5/5/26 |